Cynata Therapeutics
(ASX:CYP) has announced it commenced patient dosing in the first ever clinical trial of stem cell therapy for graft-versus host disease therapy.
The Australian stem cell and regenerative medicine company says the trial is a major achievement in the evolution of the company.
The company's Phase 1 trial of CYP-001 is also being recruited at six centres in the UK and Australia.
At the same time, Cynata Therapeutics also announced it secured over $60 million through a FUJIFILM partnership and a license option for CYP-001 in graft-versus host disease (GvHD)
Shares in Cynata Therapeutics
(ASX:CYP) are trading 3.1 per cent higher to $0.66.
